Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Summary not available.
Summary not available.
Nurix Therapeutics has announced key findings from its presentations at the AACR Annual Meeting, focusing on its lead BTK degrader, NX-2127, and the investigational compound NX-5948. Both compounds exhibit significant efficacy against BTK inhibitor resistance mutations in B-cell malignancies. The results reveal that NX-5948 promotes selective degradation of multiple BTK resistance mutations, outperforming other reported BTK degraders.
NX-2127's structure was first disclosed during this event, alongside preclinical data and initial pharmacokinetic information. These advancements strengthen the rationale for the ongoing clinical trials evaluating these compounds in patients with advanced B-cell malignancies, potentially offering new treatment avenues for patients unresponsive to existing therapies.
Nurix Therapeutics (Nasdaq: NRIX) announced a productive start to 2023, highlighted by Gilead's licensing of NX-0479/GS-6791, a targeted protein degrader of IRAK4, generating a $20 million upfront payment. The collaboration aims to explore applications in rheumatoid arthritis and other inflammatory diseases, offering potential additional milestone payments of up to $425 million. First-quarter collaboration revenue increased to $12.7 million, up from $9.6 million year-over-year, supported by $7.5 million in research milestones from Gilead and Sanofi. However, the company's net loss for the quarter was $40.7 million, or $0.75 per share, down from a loss of $42.5 million or $0.95 per share a year prior. Cash and marketable securities stand at $325.6 million as of February 28, 2023.
Nurix Therapeutics, a clinical-stage biopharmaceutical company focused on targeted protein modulation for treating cancer, announced that President and CEO Arthur T. Sands, M.D., Ph.D., will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 3:00 p.m. ET. The event will be available for live streaming, and an archived version will be accessible on the company's website for 30 days post-event.
Nurix's innovative approach includes the discovery and development of small molecules and cell therapies that modulate cellular protein levels using E3 ligases. Their proprietary DELigase platform enables the identification of novel drug candidates targeting E3 ligases, aimed at treating hematologic malignancies and solid tumors. For more information, visit Nurix's website.
Nurix Therapeutics and Gilead Sciences have announced that Gilead has exercised an option to exclusively license Nurix's investigational protein degrader molecule, NX-0479, now designated GS-6791. This trigger represents a major milestone in their 2019 collaboration, providing Nurix with a $20 million option fee, with additional potential payments of up to $425 million dependent on various milestones. GS-6791, a selective IRAK4 degrader, targets inflammatory responses in conditions like rheumatoid arthritis. This development highlights the strategic significance of their collaboration and Nurix's innovative DELigase platform for advancing therapeutic candidates.
Nuri Therapeutics (Nasdaq: NRIX) announced the upcoming presentation of preclinical data on its targeted BTK degraders, NX-2127 and NX-5948, at the AACR 2023 Annual Meeting in Orlando, FL, from April 14-19, 2023. Both compounds are undergoing Phase 1 trials for patients with relapsed or refractory B cell malignancies. Key presentations include NX-2127 as a first-in-class degrader of BTK and IKZF1/3 as well as NX-5948, which selectively degrades inhibitor-resistant BTK mutants. Details will be available for on-demand viewing starting April 14, 2023. Nurix focuses on innovative therapies aimed at modulating protein levels for cancer treatment.
Nurix Therapeutics (Nasdaq: NRIX) will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:40 a.m. ET. The presentation by Arthur T. Sands, M.D., Ph.D., the company's president and CEO, will be available via webcast on the Nurix website in the Investors section. The archived webcast will be accessible for 30 days post-event. Nurix, a clinical-stage biopharmaceutical company, focuses on developing targeted protein modulation drugs for cancer treatment. Its proprietary platform, DELigase, aids in discovering novel drug candidates targeting E3 ligases.
Nurix Therapeutics (Nasdaq: NRIX) announced significant advancements in their clinical programs and financial results for the year ended November 30, 2022. The company reported a year-end cash position of $373 million. Highlights included promising clinical data for NX-2127, demonstrating efficacy against BTK inhibitor resistance mutations. Collaboration revenues rose from $29.8 million to $38.6 million year-over-year. However, the net loss increased to $180.4 million compared to $117.2 million in the previous year, with R&D expenses up 58% to $184.5 million.
Nurix Therapeutics (Nasdaq: NRIX) announced participation in key conferences this February, focusing on developments in targeted protein modulation for treating cancers. The SVB Securities Global Biopharma Conference will feature a fireside chat with CEO Arthur T. Sands on February 15. Following that, the Wells Fargo Targeted Protein Degradation Virtual Summit on February 21 includes panels with Sands and CSO Gwenn M. Hansen, covering critical topics like overcoming resistance and the role of targeted protein degradation. These events will be webcast live and archived for 30 days on the Nurix website, enhancing accessibility for investors and stakeholders.